A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Abstract
Key Points IMGN632 is a conjugate of a novel CD123-targeting antibody with a highly potent DNA alkylating payload. IMGN632 is active in preclinical models of AML with poor prognosis at concentrations far below levels that impact normal bone marrow...
Paper Details
Title
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Published Date
Apr 16, 2018
Journal
Volume
2
Issue
8
Pages
848 - 858
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History